Table 1 Clinical characteristics of breast cancers in mutation carriers and non-carriers
From: Genetic predisposition to male breast cancer in Poland
Mutation | BRCA1 | BRCA2 | PALB2 | CHEK2 truncating | CHEK2 c.470C > T | NBN | Non-carriers | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
N | Tot | % | N | Tot | % | N | Tot | % | N | Tot | % | N | Tot | % | N | Tot | % | N | Tot | % | |
Histology | |||||||||||||||||||||
 Ductal | 1 | 1 | 100.0 | 2 | 2 | 100.0 | 3 | 3 | 100.0 | 4 | 4 | 100.0 | 7 | 8 | 87.5 | 1 | 1 | 100.0 | 111 | 125 | 88.8 |
 Lobular | 0 | 1 | 0.0 | 0 | 2 | 0.0 | 0 | 3 | 0.0 | 0 | 4 | 0.0 | 0 | 8 | 0.0 | 0 | 1 | 0.0 | 6 | 125 | 4.8 |
 Other | 0 | 1 | 0.0 | 0 | 2 | 0.0 | 0 | 3 | 0.0 | 0 | 4 | 0.0 | 1 | 8 | 12.5 | 0 | 1 | 0.0 | 8 | 125 | 6.4 |
Tumour size | |||||||||||||||||||||
 T1/T2 | 0 | 1 | 0.0 | 2 | 2 | 100.0 | 2 | 3 | 66.7 | 3 | 3 | 100.0 | 7 | 7 | 100.0 | 1 | 1 | 100.0 | 83 | 110 | 75.5 |
 T3/T4 | 1 | 1 | 100.0 | 0 | 2 | 0.0 | 1 | 3 | 33.3 | 0 | 3 | 0.0 | 0 | 7 | 0.0 | 0 | 1 | 0.0 | 27 | 110 | 24.5 |
ER positive | 1 | 1 | 100.0 | 1 | 1 | 100.0 | 3 | 3 | 100.0 | 4 | 4 | 100.0 | 7 | 7 | 100.0 | 1 | 1 | 100.0 | 100 | 111 | 90.0 |
PR positive | 1 | 1 | 100.0 | 1 | 1 | 100.0 | 3 | 3 | 100.0 | 4 | 4 | 100.0 | 7 | 7 | 100.0 | 1 | 1 | 100.0 | 88 | 110 | 80.0 |
HER2 positive | 0 | 1 | 0.0 | 0 | 1 | 0.0 | 0 | 3 | 0.0 | 0 | 4 | 0.0 | 1 | 7 | 14.3 | 1 | 1 | 100.0 | 11 | 108 | 10.2 |
Triple negative | 0 | 1 | 0.0 | 0 | 1 | 0.0 | 0 | 3 | 0.0 | 0 | 4 | 0.0 | 0 | 7 | 0.0 | 0 | 1 | 0.0 | 11 | 107 | 10.3 |
Lymph nodes positive | 0 | 1 | 0.0 | 2 | 2 | 100.0 | 1 | 3 | 33.3 | 1 | 3 | 33.3 | 1 | 7 | 14.3 | 0 | 1 | 0.0 | 53 | 104 | 51.0 |
Bilateral | 0 | 1 | 0.0 | 0 | 2 | 0.0 | 2 | 4 | 50.0 | 0 | 5 | 0.0 | 0 | 9 | 0.0 | 0 | 1 | 0.0 | 0 | 143 | 0.0 |
Multiple primary cancers | 0 | 1 | 0.0 | 2 | 2 | 100.0 | 2 | 4 | 50.0 | 1 | 5 | 20.0 | 3 | 9 | 33.3 | 0 | 1 | 0.0 | 12 | 143 | 8.4 |
Family history positive | |||||||||||||||||||||
 Breast | 1 | 1 | 100.0 | 1 | 2 | 50.0 | 3 | 4 | 75.0 | 2 | 5 | 40..0 | 2 | 9 | 22.2 | 0 | 1 | 0.0 | 38 | 143 | 26.6 |
 Ovarian | 0 | 1 | 0.0 | 0 | 2 | 0.0 | 1 | 4 | 25.0 | 0 | 5 | 0.0 | 0 | 9 | 0.0 | 0 | 1 | 0.0 | 6 | 143 | 4.2 |
 Other | 0 | 1 | 0.0 | 1 | 2 | 50.0 | 0 | 4 | 0.0 | 3 | 5 | 60.0 | 5 | 9 | 55.6 | 0 | 1 | 0.0 | 51 | 143 | 35.7 |
Age of diagnosis | |||||||||||||||||||||
  < 50 | 0 | 1 | 0.0 | 0 | 2 | 0.0 | 2 | 4 | 50.0 | 1 | 5 | 20.0 | 2 | 9 | 22.2 | 0 | 1 | 0.0 | 20 | 143 | 14.0 |
  ≥ 50 | 1 | 1 | 100.0 | 2 | 2 | 100.0 | 2 | 4 | 50.0 | 4 | 5 | 80.0 | 7 | 9 | 77.8 | 1 | 1 | 100.0 | 123 | 143 | 86.0 |
Median age of diagnosis (range) | 74 | 69 (62–76) | 57 (42–77) | 62 (33–70) | 64 (34–72) | 62 | 63 (26–89) | ||||||||||||||